Advertisement

Topics

Latest Biotechnology, Pharmaceutical and Healthcare News from ChinaBio Today

04:16 EST 16th December 2018 | BioPortfolio

Here are the most relevant search results for "ChinaBio Today" found in our extensive news archives from over 250 global news sources.

More Information about ChinaBio Today on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about ChinaBio Today for you to read. Along with our medical data and news we also list ChinaBio Today Clinical Trials, which are updated daily. BioPortfolio also has a large database of ChinaBio Today Companies for you to search.

Showing News Articles 1–25 of 406 from ChinaBio Today

Saturday 15th December 2018

Week in Review: Two China Biopharmas Raise $1.4 Billion in Hong Kong IPOs

Deals and Financings  WuXi AppTec, China's largest CRO/CMO, completed its $967 million IPO in Hong Kong and finished its first trading day at the offer price; Shanghai Junshi Bioscience will raise up to $414 million in a Hong Kong IPO to support its antibody portfolio, including the first PD-1 candidate with an accepted China NDA; WuXi Biologics formed a $450 million partnership with Oxford ...

Friday 14th December 2018

Cerveau Announces Singapore Test of Neuro PET Imaging Agent

Cerveau Technologies, a partnership between Beijing Sinotau Pharma and Enigma Biomedical of Toronto, will start a Singapore trial of its PET imaging agent for neurofibrillary tangles (NFTs) in the brain, the first Asia test of the agent. Cerveau develops diagnostics and technology for neurodegenerative disorders including Alzheimer's disease. It in-licensed global rights to the agent, MK-6240, fro...

WuXi AppTec Completes Hong Kong IPO; Finishes First Trading Session Unchanged

WuXi AppTec began trading on the Hong Kong Exchange following its $967 million IPO, finishing the first day of trading at the offer price. In May, the company completed a $354 million Shanghai IPO at a price that has now quadrupled after six months. From the start, WuXi planned to have a dual Shanghai-Hong Kong listing, following the low-priced Shanghai IPO with a higher priced Hong Kong offering....

Thursday 13th December 2018

Innovent Sees Positive Data from China Phase III Trial of Avastin Biosimilar

Suzhou Innovent Biologics reported its Avastin biosimilar produced positive results in two China clinical trials. IBI305, a VEGF inhibitor, met its primary endpoints in two randomized clinical trials that compared the candidate to Roche's Avastin: 1) a Phase III trial in 450 patients with advanced non-squamous non-small cell lung cancer (NSCLC) and 2) a pharmacokinetic study in 100 healthy volunte...

Zai Lab's NDA for PARP Inhibitor Accepted for China Review

Zai Lab of Shanghai announced that the China National Medical Products Administration (NMPA) accepted its NDA for Zejula (niraparib), a novel Category 1 PARP1/2 drug -- the first Zai NDA submission accepted in China. The candidate is indicated for maintenance treatment of patients with recurrent ovarian and fallopian tube cancer who are in a complete or partial response to platinum-based chemother...

Wednesday 12th December 2018

Lonza to Build Biologics CDMO in China Using GE's Prefabricated Factory

Lonza Group, a Swiss company that offers CDMO services and lab products, announced plans to partner with GE Healthcare to build a biologics manufacturing facility in Guangzhou, using GE's KUBio platform. Because the prefabricated facility reduces construction/approval times, Lonza expects it will be operational in 2020. Previously, Lonza offered CDMO scale-up and production for APIs in China, also...

WuXi Biologics Announces $450 Million Bispecific Deal with Oxford BioTherapeutics

WuXi Biologics formed a $450 million partnership with England's Oxford BioTherapeutics to develop five novel bispecific antibodies, including a PD-L1 molecule, using its WuXiBody™ Platform. OBT says the bispecifics will combine two second-gen immunoncology targeting mechanisms in a single molecule to improve efficacy. Oxford will make an upfront payment plus milestones and royalties, though ...

Shanghai Junshi Bioscience to Raise $414 Million in Hong Kong IPO

Shanghai Junshi Bioscience plans to raise up to $414 million in a Hong Kong IPO that will be priced later this week and begin trading on December 24. The IPO values Junshi at $1.9 billion. Seven cornerstone investors have agreed to buy $242 million of the offering. Founded in 2012, Junshi is developing immunoncology candidates and other biologics. It claims to be the first China company to file an...

Tuesday 11th December 2018

WuXi Biologics Forms BiSpecifics Collaboration with Brii Bio

WuXi Biologics will collaborate with Brii Biosciences, a China-US startup, to discover novel bispecific targets for infectious diseases and other immunologic disorders. WuXi will employ its WuXiBody™ technology to discover the bispecific antibodies, and it will be Brii Bio's exclusive development and manufacturing partner for any novel bispecific antibodies. WuXi said its platform develops c...

Monday 10th December 2018

HiFiBiO Forms JV to Develop Novel Cancer Research

HiFiBiO Therapeutics, a Boston-Paris-Shanghai company, has formed an immune modulation JV, Victa Biotherapeutics, with Vikas P. Sukhatme, MD. Using Dr. Sukatme's research, the JV will develop drug candidates based on myeloid-derived suppressor cells (MDSCs). HiFiBiO will apply its single-cell profiling expertise to identify first-in-class antibodies for various cancer indications. HiFiBiO dev...

Sunday 9th December 2018

Week in Review: China Pharmas Announce Deals Worth $1.5 Billion

Deals and Financings  WuXi AppTec raised $1 billion in a Hong Kong IPO, which it will use to expand its CRO/CMO operations in China and globally; Shanghai Fosun Pharma in-licensed rights to a Revance next-gen botox candidate for aesthetic and therapeutic use in a $260 million deal; Brii Biosciences, a China-US startup, entered a $128.5 million agreement for China rights to a hepatitis B vacc...

Saturday 8th December 2018

China Conducts Drug Tenders for Shanghai Market; Prices Drop 46%

On Thursday, China began the tendering process to supply drugs in 11 major China cities. The government wants to cut prices for generic drugs, and the process was more successful than experts predicted. China pharmas -- and multinationals -- offered their products at prices that were up to 90% lower, creating fear that winners of the tendering process might be worse off than the losers. In all, co...

WuXi AppTec Raises $1 Billion in Hong Kong IPO

WuXi AppTec, China's largest CRO/CMO, completed a $1 billion IPO on the Hong Kong markets, pricing the offering in the middle of the expected range. In May, WuXi became a public company by completing a $328 million IPO in Shanghai. Since the offering, the company's shares have nearly quadrupled. The Hong Kong offering was completed at a $10 billion valuation, about a 16% discount to its valuation ...

Friday 7th December 2018

China Approves Mundipharma China/Helsinn Anti-Emetic Treatment

Mundipharma China of Beijing and Helsinn, a Swiss pharma, announced China approval to market Aloxi® IV, a preventative treatment for nausea and vomiting caused by chemotherapy. Aloxi is a 5-HT3 receptor antagonist. In 2017, Mundipharm acquired China rights to Aloxi and also Akynzeo®, a fixed dose oral combination anti-emetic from Helsinn. For Helsinn, the approval is its first product...

Brii Bio Forms $128.5 Million Collaboration for Therapeutic Hepatitis B Vaccine

Brii Biosciences, a China-US startup, has entered a $128.5 million agreement for China rights to an immuno-therapeutic hepatitis B vaccine from VBI Vaccines of Cambridge, MA. Brii made a $4 million upfront payment and an equity investment of $11 million in VBI, plus will pay up to $117.5 million in milestones. Brii made its debut earlier this year with $260 million in initial capital. It also anno...

Thursday 6th December 2018

Fosun Pharma Acquires Rights to Next-Gen Botox-type Drug in $260 Million Deal

Shanghai Fosun Pharma in-licensed rights to a Revance (NSDQ: RVNC) neuromodulator for aesthetic and therapeutic use in an agreement potentially worth $260 million. Fosun will pay $30 million upfront and up to $230 million in milestones, plus royalties. The first neuromodulator with long-acting duration, DaxibotulinumtoxinA (RT002) is also the first Botox-type product formulated without human blood...

Innovent Approved to Start US Trials of Novel Immunotherapy

Suzhou Innovent Biologics was approved to start US clinical trials of its recombinant fully human anti-OX40 mAb, which Innovent intends to test in patients with solid tumors. IBI101, the third Innovent candidate to start US trials, targets the tumor necrosis factor receptor superfamily member 4. Eventually, the company plans to test IBI101 in combination with other immunotherapies, including its o...

Fresenius Building China Dialysis Centers Network through Acquisitions

Germany's Fresenius Medical, a global company that makes renal care products and operates dialysis clinics, announced several acquisitions that will extend its China network of dialysis clinics. Fresenius claims to be the largest dialysis device maker and clinic operator in the world. It has been active in China since the early 1980s, operates four manufacturing sites in the country and is the mar...

Wednesday 5th December 2018

Legend/Janssen CAR-T Therapy Posts Strong Results in Multiple Myeloma Trial

Legend Biotech of Nanjing reported positive data from a China Phase I/II trial of its CAR-T therapy in a heavily pre-treated population of multiple myeloma patients. In a trial that enrolled 57 patients, LCAR-B38M produced a complete response in 74% of the patients and an overall response rate of 88%. In 2017, Legend stunned the world with an overall response rate of over 90% in a small initial tr...

Shenzhen Salubris Invests $10 Million in Viracta; Signs $58 Million Deal for Cancer Drug

Shenzhen Salubris Pharma invested $10 million in Viracta Therapeutics of San Diego. Salubris also acquired greater China rights to Viracta's clinical-stage treatment for Epstein Barr Virus (EBV)-associated lymphomas in a deal that includes $58 million in development milestones, plus unspecified commercial milestones and tiered royalties. The treatment is the first targeted, oral therapy for EBV-as...

Tuesday 4th December 2018

Immunochina Collaborates with Sartorius Stedim for CAR-T Production

Immunochina, a Beijing biotech, will collaborate with Sartorius Stedim Biotech using SSB’s bioprocess technology platform to develop and manufacture Immunochina's CAR-T therapies. Immunochina will provide technical feedback to SSB. Immunochina's lead program targets CD19 in B-Cell Acute Lymphoblastic Leukemia (B-ALL) and Non-Hodgkin's Lymphoma. In a B-ALL trial, the CAR-T candidate achieved ...

CASI Pharma Approved to Launch Melphalan in China

CASI Pharma, a US-China company, was granted approval to market melphalan hydrochloride for injection (Evomela®) in China for use as a multiple myeloma treatment. The drug has two indications: a high-dose conditioning treatment prior to hematopoietic progenitor (stem) cell transplantation in patients with multiple myeloma, and palliative treatment of patients with multiple myeloma for whom ora...

Elpiscience of Shanghai Raises $35 Million to Develop Immunotherapies

Elpiscience, a Shanghai immunoncology company, closed a $35 million Series B round led by Hillhouse Capital. Elpiscience has licensed technology from regional institutions and global partnerships to develop its pipeline, which now includes more than 10 molecules targeting novel pathways in cancer immunotherapy, including two assets that are ready for IND filing. In 2017, Elpiscience closed a ...

Sunday 2nd December 2018

Week in Review: BeiGene Forges $1.3 Billion Bi-Specific Antibody Deal with Zymeworks

Deals and Financings BeiGene of Beijing acquired China rights to two Zymeworks bispecific antibodies and global rights to three to-be-discovered candidates in a $1.3 billion deal; WuXi AppTec, China's largest CRO/CMO, will price its $1 billion IPO in Hong Kong on December 6 and begin trading one week later; WuXi NextCODE closed a $200 million Series C financing, acquired Genomics Medicine Irelan...

Saturday 1st December 2018

Biohaven Sets Up China Subsidiary for Migraine/CNS Drugs

US-Based Biohaven Pharma formed a Shanghai subsidiary, BioShin™, to develop and commercialize its late-stage migraine and neurology portfolio in China and other Asia-Pacific markets. To build its portfolio, Biohaven has combined internal R&D with in-licensings from biopharmas and institutions. Earlier this week, the company filed a US NDA for a sublingual formulation of the ALS drug rilu...


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks